Our studies may offer some explanation as to the aetiology of PASMC proliferation that may be of relevance to PAH onset and progression and, potentially a therapeutic option via intervention to target the hepcidin/ferroportin axis, or via IL-6 antagonists. The gene discussed is SLC40A1; the disease is pulmonary arterial hypertension.